U.S. Markets close in 2 hrs 35 mins

SHAREHOLDER ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit against Kitov Pharmaceuticals Holdings LTD and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--

Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Kitov Pharmaceuticals Holdings LTD (“Kitov” or the “Company”) (KTOV) on behalf of all those who purchased Kitov American Depositary Receipts (“ADRs”) pursuant to the Company’s initial public offering on or about November 20, 2015 (the “IPO”) and/or between November 20, 2015 and February 3, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the IPO or the Class Period, are encouraged to contact the firm in advance of the April 10, 2017 lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we encourage you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights free of charge. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Complaint alleges that throughout the Class Period, Kitov made false and/or misleading statements and/or failed to disclose that the Company and its CEO Isaac Israel, published misleading information concerning the conduct of the Company’s clinical trials for its lead drug candidate, KIT-302, and consequently, Kitov’s public statements were materially false and misleading at all relevant times. On February 6, 2017, Calcalist, an Israeli publication, reported that Isaac Israel had been detained and questioned by the Israeli Securities Authority for allegedly publishing misleading information about the Company’s recent clinical trial. When this news was revealed to the public, shares of Kitov fell in value, causing investors harm.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170327006235/en/